The Risk of Tuberculosis and TNF-alpha Inhibitors

Acar M., Sutcu M., Salman N., Sourer A.

JOURNAL OF PEDIATRIC INFECTION, cilt.11, sa.2, 2017 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 11 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5578/ced.201719
  • Dergi Adı: JOURNAL OF PEDIATRIC INFECTION
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • İstanbul Üniversitesi Adresli: Evet

Özet

The clinical use of TNF-alpha inhibitors have been increasing in the treatment of autoimmune disorders. The most common anti-TNF-alpha agents on clinical use are ethanercept, infliximab and adalimumab. TNF-alpha is an important mediator in the pathogenesis of tuberculosis, therefore the use of TNFAI increases the risk of tuberculosis. Patients who are on anti-TNF alpha treatment should be carefully evaluated for tuberculosis risk before and during therapy. The recommended screening tools are detailed history, physical examination, tuberculin skin test and/or interferon gamma (IFN-gamma) release assay and chest X-Ray every six months.